0000950170-24-043502.txt : 20240410 0000950170-24-043502.hdr.sgml : 20240410 20240410205027 ACCESSION NUMBER: 0000950170-24-043502 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240408 FILED AS OF DATE: 20240410 DATE AS OF CHANGE: 20240410 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FRIEDMAN PAUL A CENTRAL INDEX KEY: 0001236927 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33277 FILM NUMBER: 24836949 MAIL ADDRESS: STREET 1: C/O INCYTE CORPORATION STREET 2: 1801 AUGUSTINE CUT-OFF CITY: WILMINGTON STATE: DE ZIP: 19803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MADRIGAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001157601 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 BUSINESS PHONE: 404-380-9263 MAIL ADDRESS: STREET 1: 200 BARR HARBOR DRIVE, SUITE 400 CITY: WEST CONSHOHOCKEN STATE: PA ZIP: 19428 FORMER COMPANY: FORMER CONFORMED NAME: SYNTA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20010815 4 1 ownership.xml 4 X0508 4 2024-04-08 0001157601 MADRIGAL PHARMACEUTICALS, INC. MDGL 0001236927 FRIEDMAN PAUL A C/O MADRIGAL PHARMACEUTICALS, INC. 200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428 true false false false true Common Stock 2024-04-08 4 M false 26270 9.45 A 212005 D Common Stock 2024-04-08 4 S false 1441 242.9523 D 210564 D Common Stock 2024-04-08 4 S false 3730 244.1197 D 206834 D Common Stock 2024-04-08 4 S false 5663 244.8607 D 201171 D Common Stock 2024-04-08 4 S false 2078 245.7126 D 199093 D Common Stock 2024-04-08 4 S false 5028 246.9590 D 194065 D Common Stock 2024-04-08 4 S false 3464 247.7601 D 190601 D Common Stock 2024-04-08 4 S false 4866 248.5907 D 185735 D Common Stock 655540 I By SQN LLC Stock Option (Right to Buy) 9.45 2024-04-08 4 M false 26270 0 D 2026-07-22 Common Stock 26270 206256 D These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.39 to $243.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.43 to $244.42, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.43 to $245.42, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.43 to $246.28, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.45 to $247.43, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.47 to $248.24, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.47 to $248.64, inclusive. The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. The shares underlying this stock option are fully vested and exercisable. /s/ Mardi Dier, as Attorney-in-Fact 2024-04-10